Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in GANX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 1.8M | $3.4M | +6.5% | 4.149% | 0.00% |
| 2 | Potomac Capital Management, Inc. | 1.0M | $2.0M | -0.1% | 2.365% | 1.70% |
| 3 | JONES FINANCIAL COMPANIES LLLP | 632K | $1.2M | -10.1% | 1.481% | 0.00% |
| 4 | DME Capital Management, LP | 566K | $1.1M | 0.0% | 1.327% | 0.03% |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 470K | $911K | -35.6% | 1.101% | 0.00% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 447K | $869K | +12.4% | 1.049% | 0.00% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 400K | $776K | β | 0.938% | 0.00% |
| 8 | VANGUARD FIDUCIARY TRUST CO | 230K | $446K | β | 0.539% | 0.00% |
| 9 | BlackRock, Inc. | 225K | $437K | +7.4% | 0.528% | 0.00% |
| 10 | UBS Group AG | 220K | $428K | +171.8% | 0.517% | 0.00% |
| 11 | Cresset Asset Management, LLC | 160K | $310K | 0.0% | 0.375% | 0.00% |
| 12 | STATE STREET CORP | 158K | $306K | 0.0% | 0.369% | 0.00% |
| 13 | MORGAN STANLEY | 140K | $271K | -5.4% | 0.327% | 0.00% |
| 14 | Stratos Wealth Partners, LTD. | 132K | $255K | β | 0.309% | 0.00% |
| 15 | NORTHERN TRUST CORP | 114K | $221K | +11.8% | 0.267% | 0.00% |
| 16 | LPL Financial LLC | 104K | $202K | -2.2% | 0.244% | 0.00% |
| 17 | CITADEL ADVISORS LLC | 71K | $137K | β | 0.166% | 0.00% |
| 18 | PRELUDE CAPITAL MANAGEMENT, LLC | 36K | $69K | 0.0% | 0.084% | 0.01% |
| 19 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 30K | $58K | 0.0% | 0.070% | 0.00% |
| 20 | COMMONWEALTH EQUITY SERVICES, LLC | 30K | $58K | +134.2% | 0.070% | 0.00% |
| 21 | Apollon Wealth Management, LLC | 27K | $51K | +33.7% | 0.062% | 0.00% |
| 22 | Schonfeld Strategic Advisors LLC | 25K | $48K | β | 0.057% | 0.00% |
| 23 | Oliver Luxxe Assets LLC | 20K | $39K | 0.0% | 0.048% | 0.01% |
| 24 | Vanguard Global Advisers, LLC | 18K | $36K | β | 0.043% | 0.00% |
| 25 | Wealthspire Advisors, LLC | 17K | $33K | 0.0% | 0.040% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in GANX β a direct measure of their conviction.
Filings activity in GANX during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 39 | 17% | 19.26% | 14.16 pp | $14M | 42% |
| Q4 2025 | 47 | +27% | 33.42% | +23.65 pp | $24M | +242% |
| Q3 2025 | 37 | +5.7% | 9.77% | 6.27 pp | $7M | 39% |
| Q2 2025 | 35 | +9.4% | 16.04% | +5.88 pp | $11M | +58% |
| Q1 2025 | 32 | +33% | 10.16% | 0.31 pp | $7M | 3.0% |
| Q4 2024 | 24 | +26% | 10.47% | 3.12 pp | $8M | 23% |
| Q3 2024 | 19 | 34% | 13.59% | +8.23 pp | $10M | +154% |
| Q2 2024 | 29 | β | 5.36% | β | $4M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying GANX stock.
Based on Q1 2026 13F filings, institutional ownership of Gain Therapeutics, Inc. stands at 19.3%, held across 39 reporting institutions.
MARSHALL WACE, LLP is the largest reported institutional holder of GANX, with approximately 1,769,788 shares worth $0.00B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of GANX, including SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC.
Our composite Smart Money Score for GANX is 36 out of 100 (Bearish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
9 institutions opened new positions in GANX during Q1 2026, while 17 fully exited. 4 added to existing positions and 26 trimmed.
GANX institutional ownership fell by 14.16 percentage points quarter-over-quarter, with a net change of -8 holders.
The top 10 institutions account for 83.4% of all reported 13F value in GANX, and the top 25 account for 98.6%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Gain Therapeutics, Inc. (GANX) Institutional Ownership